Greeting

In recent years, remarkable progress has been made in cancer treatment. Although the "fourth pillar" of cancer therapy - which regulates the body's immune function using targeted therapies such as antibody drugs and immune checkpoint inhibitors - is becoming increasingly prevalent, the current reality is that these treatments are not effective for all cancer types. Many cancers still represent high unmet medical needs without definitive cures, driving a critical demand for novel pharmaceuticals and therapeutic approaches. 

Conventional cancer immunotherapies utilizing a patient's own cells includemethods that activate immune cells non-specifically or target only specific cancer antigens. However, these approaches continue to face unresolved challenges, such as limited therapeutic efficacy and low durability.

It is widely believed that the future of cancer immunotherapy lies in enabling immune cells to "remember the cancer" while attacking it in a "cancer-antigen-specific" manner. In other words, patients must acquire an immune defense system where memory cells can mount a renewed attack even if the cancer recurs.

Accellvecs Inc has developed "SynVC", an innovative therapy designed to establish and imprint cancer-antigen-specific immunity by presenting all the cancer antigens derived from a patient's own tumor cells or tissues to their internal immune cells.

Furthermore, we have initiated the provision of "Cancer Metabolic Immunotherapy" as a fifth pillar of treatment, adding a novel approach to reverse immune cell exhaustion to the existing fourth pillar. Moving forward, we aim to develop new drug formulations for Cancer Metabolic Immunotherapy and actively pursue drug repositioning.